Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Down 5.1% – Here’s What Happened

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) was down 5.1% on Tuesday. The company traded as low as $10.79 and last traded at $10.7450. 128,543 shares were traded during trading, a decline of 90% from the average daily volume of 1,252,757 shares. The stock had previously closed at $11.32.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on ZVRA shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Zevra Therapeutics in a research report on Wednesday, August 19th. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research report on Thursday, August 6th. BTIG Research dropped their price objective on shares of Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Monday, July 27th. UBS Group reaffirmed a “buy” rating on shares of Zevra Therapeutics in a research note on Thursday, August 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $26.00 target price on shares of Zevra Therapeutics in a report on Thursday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $27.14.

Zevra Therapeutics Trading Down 6.7%

The firm has a market capitalization of $626.99 million, a price-to-earnings ratio of 11.46 and a beta of 0.98. The company has a fifty day moving average price of $11.54 and a two-hundred day moving average price of $11.40.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.14. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. The business had revenue of $39.66 million during the quarter, compared to analyst estimates of $33.88 million. As a group, equities research analysts expect that Zevra Therapeutics, Inc. will post 0.72 earnings per share for the current year.

Insiders Place Their Bets

In other Zevra Therapeutics news, Director Corey Watton sold 12,300 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $11.25, for a total transaction of $138,375.00. Following the transaction, the director owned 1,800 shares of the company’s stock, valued at approximately $20,250. The trade was a 87.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 3.70% of the company’s stock.

Institutional Trading of Zevra Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC purchased a new position in shares of Zevra Therapeutics during the 2nd quarter worth $28,000. Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new stake in shares of Zevra Therapeutics in the fourth quarter valued at about $53,000. Tidal Investments LLC purchased a new stake in shares of Zevra Therapeutics in the second quarter valued at about $150,000. DGS Capital Management LLC purchased a new stake in shares of Zevra Therapeutics in the fourth quarter valued at about $133,000. Finally, WINTON GROUP Ltd increased its position in Zevra Therapeutics by 49.0% during the second quarter. WINTON GROUP Ltd now owns 24,335 shares of the company’s stock worth $349,000 after purchasing an additional 8,001 shares during the last quarter. 35.03% of the stock is owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company seeks to address conditions with significant unmet medical needs by combining patient-focused drug development with proprietary technologies designed to improve the delivery and development of medicines.

Zevra’s lead product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children two years of age and older, in combination with miglustat.